文献速递临床试验与 GCP

阿加曲班联合静脉阿替普酶与单用静脉阿替普酶对急性缺血性卒中患者神经功能的影响:ARAIS随机临床试验

Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项多中心、开放标签、盲法终点随机临床试验在中国50家医院纳入808例急性缺血性卒中患者,随机分为阿加曲班联合阿替普酶组(n=402)与单用阿替普酶组(n=415)。90天时,联合组63.8%(210/329)与单用组64.9%(238/367)达到极佳功能结局,风险差-1.0%(95%CI -8.1%至6.1%),风险比0.98(95%CI 0.88-1.10),P=0.78,差异无统计学意义。

要点

  • 阿加曲班联合阿替普酶与单用阿替普酶相比,90天极佳功能结局无显著差异。
  • 联合组症状性颅内出血2.1%(8/383),单用组1.8%(7/397)。
  • 联合组实质型血肿2型2.3%(9/383),单用组2.5%(10/397)。

核心结论

  • 在急性缺血性卒中患者中,与单用静脉阿替普酶相比,阿加曲班联合静脉阿替普酶并未显著提高90天极佳功能结局的可能性。

研究设计与样本

  • 多中心、开放标签、盲法终点随机临床试验,在中国50家医院开展,纳入808例急性缺血性卒中患者。
  • 入组时间为2019年1月18日至2021年10月30日,最终随访时间为2022年1月24日。
  • 患者随机分为阿加曲班联合阿替普酶组(n=402)与单用阿替普酶组(n=415),两组均接受指南推荐治疗。

主要发现

  • 90天时,联合组63.8%(210/329)与单用组64.9%(238/367)达到极佳功能结局(改良Rankin量表评分0-1分),风险差-1.0%(95%CI -8.1%至6.1%),风险比0.98(95%CI 0.88-1.10),P=0.78。
  • 症状性颅内出血发生率联合组2.1%(8/383) vs 单用组1.8%(7/397)。
  • 实质型血肿2型发生率联合组2.3%(9/383) vs 单用组2.5%(10/397)。
  • 主要系统性出血发生率联合组0.3%(1/383) vs 单用组0.5%(2/397)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous studies suggested a benefit of argatroban plus alteplase (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke (AIS). However, robust evidence in trials with large sample sizes is lacking. OBJECTIVE: To assess the efficacy of argatroban plus alteplase for AIS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, blinded end point randomized clinical trial including 808 patients with AIS was conducted at 50 hospitals in China with enrollment from January 18, 2019, through October 30, 2021, and final follow-up on January 24, 2022. INTERVENTIONS: Eligible patients were randomly assigned within 4.5 hours of symptom onset to the argatroban plus alteplase group (n = 402), which received intravenous argatroban (100 μg/kg bolus over 3-5 minutes followed by an infusion of 1.0 μg/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% administered as 1-minute bolus, remaining infused over 1 hour), or alteplase alone group (n = 415), which received intravenous alteplase alone. Both groups received guideline-based treatments. MAIN OUTCOMES AND MEASURES: The primary end point was excellent functional outcome, defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 1 at 90 days. All end points had blinded assessment and were analyzed on a full analysis set. RESULTS: Among 817 eligible patients with AIS who were randomized (median [IQR] age, 65 [57-71] years; 238 [29.1%] women; median [IQR] National Institutes of Health Stroke Scale score, 9 [7-12]), 760 (93.0%) completed the trial. At 90 days, 210 of 329 participants (63.8%) in the argatroban plus alteplase group vs 238 of 367 (64.9%) in the alteplase alone group had an excellent functional outcome (risk difference, -1.0% [95% CI, -8.1% to 6.1%]; risk ratio, 0.98 [95% CI, 0.88-1.10]; P = .78). The percentages of participants with symptomatic intracranial hemorrhage, parenchymal hematoma type 2, and major systemic bleeding were 2.1% (8/383), 2.3% (9/383), and 0.3% (1/383), respectively, in the argatroban plus alteplase group and 1.8% (7/397), 2.5% (10/397), and 0.5% (2/397), respectively, in the alteplase alone group. CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke, treatment with argatroban plus intravenous alteplase compared with alteplase alone did not result in a significantly greater likelihood of excellent functional outcome at 90 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03740958.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chen HS, Cui Y, Zhou ZH, et al. Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial. JAMA. 2023. PMID: 36757755. doi:10.1001/jama.2023.0550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。